To determine whether the 16‐AHG signature could predict the outcome of BC patients independent of clinicopathological features, we performed univariate and multivariate regression analyses with gene signature, age, stage, and the status of the ER, PR, and HER2 receptors as covariates. The gene discussed is PGR; the disease is breast cancer.